Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 15;20(1):1.
doi: 10.1007/s11934-019-0866-8.

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

Caroline E Nunes-Xavier  1   2 , Javier C Angulo  3   4 , Rafael Pulido  1   5 , José I López  6   7   8
Affiliations
Review

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

Caroline E Nunes-Xavier et al. Curr Urol Rep. .

Abstract

Purpose of review: Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient's life.

Recent findings: Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing. We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.

Keywords: Clear cell renal cell carcinoma; Immune checkpoint inhibition; Immunohistochemistry; PD-1; PD-L1; Sampling protocols; Targeted therapy.

PubMed Disclaimer

References

    1. Target Oncol. 2016 Apr;11(2):143-8 - PubMed
    1. Cancer Immunol Res. 2016 Sep 2;4(9):726-33 - PubMed
    1. J Surg Oncol. 2003 Nov;84(3):166-72 - PubMed
    1. Pathol Res Pract. 2013 Mar;209(3):137-46 - PubMed
    1. Oncotarget. 2017 Jan 10;8(2):2171-2186 - PubMed

MeSH terms

Substances

LinkOut - more resources